|This Slide: #84 of 100|
Slide #84. The Medicines Company — ProFibrix
The Medicines Company (MDCO)
As previously announced, The Medicines Company entered into an agreement with ProFibrix in June 2013 to purchase all of the equity of ProFibrix B.V. subject to its review of the results of the FINISH-3 trial. Based on its review, The Medicines Company purchased all of the outstanding equity of ProFibrix for $90 million at the closing held today and agreed to pay ProFibrix equityholders up to an additional $140 million upon the achievement of agreed-upon U.S. and European regulatory approvals and sales milestones.
Medicines is a biopharmaceutical company. Co. is focused on inclisiran, the investigational RNA interference therapeutic, that inhibits production of proprotein convertase subtilisin/kexin type 9, a main protein that controls low-density lipoprotein-cholesterol levels. Co. has the right to develop, manufacture and commercialize inclisiran under its collaboration agreement with Alnylam Pharmaceuticals, Inc.
Open the MDCO Page at The Online Investor »
Free MDCO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.44 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite